Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

Developer Embark Studios releases a new ARC Raiders update for January 2026, as patch 1.11.0 brings some big balance ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no ...

Netherlands-based Scenic Biotech, a company advancing modifier therapy—a radical new approach to treating genetic ...

Friction isn’t always a flaw. When effort is intentional and optional, it can turn routine interactions into experiences ...

A significant milestone in Ocugen's development of a gene therapy for Stargardt disease has triggered a substantial rally in the company's stock. The catalyst was the publication of positive Phase 1 ...

Dungeons & Dragons' bloody handed new subclass is part Bhaalspawn, part Dark Urge, all teleporting terror - here's how to ...

Restaurant operators have spent the last decade investing in technology designed to deliver visibility: point-of-sale systems ...

You finally have a name you don’t hate. You’ve said it out loud to friends, typed it into a pitch deck, and maybe even ...

Study supports favorable safety and tolerability profile and clinically meaningful functional and structural benefits in ...

For decades, a genetic test that turned up a mutation linked to inherited blindness was treated as a verdict, not a risk ...